Forward Outlook and Clinical Insights in Melanoma Treatment

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

Now Viewing

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

In conclusion, Dr Khushalani notes much progress in improving melanoma survivorship but cautions emerging immunotherapies will likely bring more toxicities requiring adept management. He foresees greater predictive modeling and molecular testing enabling personalized toxicity risk assessments to guide informed treatment decisions. Dr Shariff expects cancer will follow other chronic diseases with greatly improved long-term outcomes thanks to advancing therapies, necessitating increased focus on survivorship care quality. Dr Moslehi closes by celebrating progress in metastatic melanoma thanks to oncology innovations, requiring a collaborative multidisciplinary approach across specialties to provide comprehensive patient care going forward.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.